New from NCI |
Video—Randomization in Clinical Trials |
| | This video explains how and why researchers randomly assign clinical trial participants to different treatment groups in some clinical trials. |
Targeted Therapy for Pancreatic Cancer
Results from a large clinical trial suggest that a targeted cancer drug already used to treat some women with ovarian and breast cancer may also benefit some people with advanced pancreatic cancer who have certain changes in the BRCA1 or BRCA2 gene. |
More Treatment Options for Metastatic Prostate Cancer |
| | Read about two large clinical trials that each tested a different antiandrogen drug combined with androgen deprivation therapy in men with metastatic prostate cancer. |
Advances in Breast Cancer Research
This page highlights some of the latest research in breast cancer, including research that may soon translate into improved care, NCI-supported programs that are fueling progress, and research findings from recent studies. |
Advances in Colorectal Cancer Research
Learn how NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat colon and rectal cancers.
|
Drug Information Updates |
New Approval for Breast Cancer
We've added a new drug information summary for alpelisib (Piqray), which was recently approved by the Food and Drug Administration (FDA) for use with fulvestrant to treat certain people with advanced or metastatic breast cancer that has a mutation in the PIK3CA gene. |
New Approval for Diffuse Large B-Cell Lymphoma
We've added a new drug information summary for polatuzumab vedotin-piiq (Polivy), which was recently approved by FDA for use with bendamustine hydrochloride and rituximab to treat certain adults with diffuse large B-cell lymphoma that has relapsed or not gotten better. |
No hay comentarios:
Publicar un comentario